RiverPark Advisors LLC Has $1.09 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

RiverPark Advisors LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 3.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,459 shares of the company’s stock after buying an additional 193 shares during the quarter. RiverPark Advisors LLC’s holdings in Zoetis were worth $1,093,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Blue Bell Private Wealth Management LLC boosted its holdings in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares during the last quarter. Webster Bank N. A. boosted its holdings in Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the last quarter. Independence Bank of Kentucky boosted its holdings in Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares during the last quarter. Private Wealth Management Group LLC bought a new position in Zoetis in the fourth quarter valued at about $33,000. Finally, Ramirez Asset Management Inc. bought a new position in Zoetis in the third quarter valued at about $35,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.7 %

Zoetis stock traded down $1.17 during midday trading on Tuesday, reaching $174.27. The stock had a trading volume of 1,777,495 shares, compared to its average volume of 2,914,421. The firm’s fifty day simple moving average is $171.62 and its 200-day simple moving average is $177.52. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The stock has a market capitalization of $79.52 billion, a P/E ratio of 33.58, a price-to-earnings-growth ratio of 2.72 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The business had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same quarter last year, the firm earned $1.31 EPS. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. As a group, analysts expect that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ZTS. Stifel Nicolaus decreased their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Barclays reduced their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. HSBC reduced their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Piper Sandler restated an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, The Goldman Sachs Group reduced their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $211.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.